What Monart Treats: Main Uses and Benefits

Monart is commonly used as a long-term controller medication for conditions involving inflammatory or irritative processes in the respiratory and nasal airways. The core therapeutic areas of use generally include prophylaxis and chronic management of asthma, symptomatic relief for allergic rhinitis, and the specific prevention of exercise-induced breathing difficulty.

This medication is applied across domains where additional symptomatic support is needed to address symptom clusters that interfere with daily functioning. It is relevant for easing challenging manifestations like persistent wheezing, chest tightness, and chronic coughing related to asthma, as well as nasal congestion, sneezing, and a runny nose caused by seasonal or perennial allergies.

This supportive relief may contribute to improved comfort during periods of heightened symptoms. The prophylactic benefit in exercise-induced situations generally assists with maintaining functional stability, and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Supportive Management of Respiratory and Nasal Symptoms

Monart is commonly used to address both the lower airway symptoms associated with persistent asthma and the upper airway symptoms common in allergic rhinitis, making it relevant for patients with coexisting conditions where symptoms may intensify temporarily.

Regulatory References

1. NIH MedlinePlus information

Who Can and Cannot Use Monart?

Eligibility for Monart (Montelukast) is strictly defined by regulatory documents, outlining which populations are permitted to use the medicine and which are excluded.

Absolute Exclusions (Contraindications)

The medicine must not be used by individuals with a known hypersensitivity to Montelukast or any component of the formulation. Furthermore, it is not indicated for the reversal of acute bronchospasm; therefore, it must not be used to treat an acute asthma attack or Status Asthmaticus.

Population Eligibility and Restrictions

Use is established for adults and adolescents (15 years and older). Pediatric eligibility is stratified by indication, established down to 12 months for chronic asthma and 6 months for perennial allergic rhinitis. Conversely, safety and effectiveness are not established for preventing exercise-induced bronchoconstriction (EIB) in children younger than six years. No dosage adjustment is required for older adults based on age alone.

Conditional Use

The prescribing label classifies use during pregnancy and lactation as restricted, permitting it only if considered clearly essential. Patients with renal impairment or mild-to-moderate hepatic impairment require no dosage adjustment. However, use in patients with severe hepatic impairment is unassessed in official documentation. The use of chewable tablets requires caution for patients with Phenylketonuria (PKU) due to the aspartame content.

Monart Interactions with other medicines and products

Pharmacokinetic Exposure Changes

The systemic concentration of Montelukast is subject to modification by co-administered medicines that affect the Cytochrome P450 (CYP) enzyme system. Co-administration with gemfibrozil, an inhibitor of CYP 2C8 and 2C9, is documented to cause a substantial pharmacokinetic interaction, resulting in a 4.4-fold increase in Montelukast systemic exposure (AUC). Conversely, potent enzyme inducers like phenobarbital can significantly decrease exposure, leading to a documented 40% reduction in Montelukast's AUC. Other inducers, including rifampicin and phenytoin, also carry the potential to reduce plasma levels.

Pharmacodynamic and Formulation Restrictions

Use is prohibited (contraindicated) with any other product containing the active ingredient Montelukast to prevent duplication of exposure. Patients who have a known sensitivity to aspirin or other NSAIDs must continue to avoid these substances, as Montelukast has not been shown to interrupt the bronchoconstrictor response in these individuals. The chewable tablet formulation contains aspartame, which is a source of phenylalanine; this is a required precaution for patients with Phenylketonuria (PKU).

Medicines with No Clinically Important Interaction

Based on regulatory studies, Monart is documented to have no clinically important effects on the pharmacokinetics of several commonly co-administered prescription drugs. These include theophylline, prednisone, prednisolone, digoxin, and warfarin. Furthermore, Montelukast may be taken with or without food, and the co-administration of oral granules with soft foods like applesauce does not affect the drug's pharmacokinetics.

Molecular Mechanism: Selective CysLT1 Receptor Blockade

Montelukast functions as a highly selective competitive antagonist, engaging the Cysteinyl Leukotriene Receptor Type 1 (CysLT1) found on key cells like airway smooth muscle and inflammatory cells. This interaction involves binding to the receptor with high affinity, thereby preventing the activation normally caused by the body's endogenous mediators, the cysteinyl leukotrienes ( LTD4, LTC4, and LTE4). This molecular blockade is the essential first step in the mechanism of action.

Functional Consequence: Modulating Airway Response

By blocking CysLT1 receptors, the drug suppresses the downstream signaling cascade that mediates CysLT-induced smooth muscle contraction and microvascular leakage in the respiratory system. The mechanism interrupts the leukotriene-mediated signal that drives the contraction of bronchial smooth muscle and reduces the signaling that promotes leakage from blood vessels, which causes tissue edema. These combined molecular actions function to maintain a reduction in basal airway smooth muscle contractility and attenuate the CysLT-mediated inflammatory response within the respiratory tissues.

Mechanistic Limitations and Specificity

The mechanism is highly specific to the CysLT1 receptor and does not antagonize the CysLT2 receptor, nor does it inhibit the upstream production of the leukotrienes themselves. However, the direct, high-affinity antagonism enables rapid pathway modulation and subsequent functional engagement.

How Monart is Used

Monart, which contains the active ingredient Montelukast, is administered via the oral route as a continuous daily medication for long-term management. The required dosage strength and formulation depend on the patient's age. Adults and adolescents aged 15 years and older typically take a 10 mg film-coated tablet once daily. Children aged 6 to 14 years are generally prescribed a 5 mg chewable tablet, while children 6 months to 5 years are assigned a 4 mg chewable tablet or oral granules. No dosage adjustment is required for older adults or individuals with mild-to-moderate hepatic or renal impairment.

Administration Timing and Schedule

The medication is strictly fixed to a once-daily schedule and can be taken with or without food. For patients managing chronic asthma or a combination of asthma and allergic rhinitis, the dose should be taken in the evening to ensure a consistent nightly regimen. If the medicine is used solely for allergic rhinitis, the time of day can be individualized to the morning or evening.

If the oral granules are used, they must be administered within 15 minutes of opening the packet, either placed directly in the mouth or mixed with soft food, breast milk, or formula; they must not be dissolved in other liquids.

Procedural Rules and Duration

Monart is intended for continuous, long-term use. If a dose is missed, the protocol is to skip the missed dose and take the next dose at the regularly scheduled time; the dose should not be doubled. For the prevention of exercise-induced breathing difficulty, a single dose must be taken at least two hours prior to exercise, but this additional dose is not to be taken if the patient is already receiving Monart daily for a chronic condition.

Research Evidence / Overview of Studies for Monart (Montelukast)

Monart (Montelukast) was studied for its role in managing certain conditions characterized by fluctuating or episodic manifestations in the respiratory system. The available research primarily consists of randomized controlled trials (RCTs), where study participants are randomly assigned to receive the medicine or a placebo, along with systematic reviews that summarize these trial findings. Research also includes long-term observational settings evaluating daily-life functioning outside of the controlled trial environment.

Evidence for Chronic Asthma Maintenance and Prophylaxis

Research examined the drug in trials involving patients undergoing long-term maintenance for asthma. The main evidence comes from short-term (4-to-12-week) RCTs that examined the patterns of asthma in patients with stable conditions. These studies included adults, adolescents, and young children (down to 12 months of age). Outcomes monitoring physiological strain or stress included objective measurements of pulmonary function, such as the forced expiratory volume in one second (FEV1), alongside patient-reported outcomes describing perceived discomfort, like the frequency of asthma exacerbations or the use of rescue medication.

Studies reported measurements of FEV1 and patient symptom scores. Findings described the patterns of change observed in the studies compared to a placebo. Variability was observed when the medicine was compared against inhaled corticosteroid therapies (ICS).

Evidence for Allergic Rhinitis (Seasonal and Perennial)

The clinical research for allergic rhinitis was evaluated in settings exploring short-term symptom changes related to seasonal and perennial allergies. Research focused on short-term (2-to-6-week) placebo-controlled RCTs that examined outcomes capturing phases of heightened symptom activity, primarily using validated nasal symptom scores. Research highlights changes measured during the study period in outcomes related to physical discomfort. Comparative evidence against other established treatments, like potent nasal steroid sprays, is limited.

Research Gaps and Unanswered Questions

Despite a large body of clinical research, certainty remains low in several key areas. Follow-up durations were limited in many of the core efficacy trials, meaning long-term effects are not fully established. Comparative evidence is lacking for many new or combination treatments, and subgroup findings are uncertain when trying to apply the results to patients with rare or complex underlying health conditions. Studies help show what has been observed so far, but research is ongoing to address these evidence gaps.

Key Studies & References

1. Montelukast: risk of mental disorders vs. efficacy–a meta-analysis (2025)

Common questions about Monart (FAQ)

Q: Is it safe to cut the tablet in half?

Whether a tablet can be cut or split is determined by the pharmaceutical form described in the official product information. This information indicates if the tablet is scored (has a line) or if it is approved for splitting to adjust the dose. If the labeling does not explicitly mention that the tablet can be split, cutting it is generally not advised, as it may affect the stability, the precise dose, or how the medicine works in the body, especially for coated or extended-release forms.

Q: Is it safe to take this with other pain relievers (e.g., ibuprofen, acetaminophen, naproxen)?

The official drug labeling contains a dedicated section listing Drug Interactions. This section specifies other medicines, including classes of drugs like pain relievers, that should not be taken with Monart. Combining certain medications can increase the risk of side effects or change the intended effect of Monart. The warnings concerning combination use with other pain relievers should be carefully reviewed.

Q: Does this medication cause hair loss?

Hair loss, or alopecia, is listed as an adverse reaction (side effect) in the official product labeling if it has been reported during clinical trials or post-marketing use. This information is found in the Undesirable Effects section of the official documents, which lists all known and suspected effects associated with the medicine based on regulatory data.

Q: Can I take this if I have a heart condition?

Official regulatory documents clearly list specific contraindications (reasons the drug must not be used) and warnings/precautions regarding pre-existing medical conditions, including heart conditions. These sections detail the risks for patients with certain cardiovascular diseases to ensure the medicine is only used appropriately. Patients with pre-existing conditions are advised to review the official warnings concerning heart conditions.

Monart (montelukast) must be stored strictly according to the conditions mandated by regulatory labeling to maintain its stability.

Storage Requirements

Stability and Disposal

The total labeled shelf-life is typically 2 years. For tablets in HDPE bottles, the limit is 30 days after opening. Oral granules must be administered within 15 minutes of opening the packet and must not be stored for later use. Any unused or expired Monart must be disposed of in accordance with local requirements for pharmaceutical waste.